Skip to main content
Veterinary Medicines

Kelactin 50 µg/ml oral solution

Authorised
  • Cabergoline

Product identification

Medicine name:
Kelactin 50 µg/ml oral solution
Veylactin vet 50 mikrog/ml oraaliliuos
Active substance:
  • Cabergoline
Target species:
  • Cat
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Cabergoline
    50.00
    microgram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral solution
Withdrawal period by route of administration:
  • Oral use
    • Cat
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG02CB03
Authorisation status:
  • Valid
Authorised in:
  • Finland
Package description:
  • Kelactin 50 µg/ml or. sol. 24 ml (glass type II)
  • Kelactin 50 µg/ml or. sol. 14 ml (glass type III)
  • Kelactin 50 µg/ml or. sol. 7 ml (glass type III)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Veyx Pharma GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Veyx Pharma GmbH
Responsible authority:
  • Finnish Medicines Agency
Authorisation number:
  • 29681
Date of authorisation status change:
Reference member state:
  • Belgium
Procedure number:
  • BE/V/0025/001
Concerned member states:
  • Cyprus
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Generic of:

Documents

Package Leaflet

English (PDF)
Published on: 16/03/2023
Download
Dutch (PDF)
Published on: 16/05/2022
Finnish (PDF)
Published on: 3/08/2023
French (PDF)
Published on: 16/05/2022
German (PDF)
Published on: 16/05/2022

Summary of Product Characteristics

English (PDF)
Published on: 16/03/2023
Download
Dutch (PDF)
Published on: 16/05/2022
Finnish (PDF)
Published on: 3/08/2023
French (PDF)
Published on: 16/05/2022

Labelling

English (PDF)
Published on: 16/03/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."